Skip to main content
OpenTrials
Completed

NCT Number: NCT00673842

Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction

This study will assess whether an implantable defibrillator will increase the likelihood of survival in patients who have had a heart attack, have abnormal test results from a 24 hour heart monitor, and who have low normal heart function.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

UZ Leuven - Campus Gasthuisberg, Leuven, Belgium

Loading trial locations.

About this study

The REFINE ICD trial will assess whether prophylactic ICD therapy, guided by non-invasive risk assessment tools, reduces mortality in MI survivors with better-preserved LV function.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Site investigators are responsible for screening. Subjects must meet all inclusion criteria. Subjects with any exclusion criteria will be excluded.

Initial inclusion criteria (eligibility for Holter screening).

  • 18 - 80 years old at time of consent
  • History of MI ≥ 2 months prior to screening based on ESC/ACCF/AHA/WHF criteria (both STEMI and NSTEMI subjects are eligible)
  • Appropriate post-MI management including revascularization where indicated
  • No contra-indication for transvenous ICD placement (e.g., mechanical tricuspid valve, known vascular access problems, active sepsis, etc.)
  • LVEF 36% - 50% measured at least 40 days after a confirmed MI ≥ 3 months after coronary angioplasty or coronary bypass surgery and within the following time windows:
  • LVEF ≤ 7 months of screening visit if index MI was ≤ 1 year of enrolment
  • LVEF ≤ 13 months of screening visit if index MI was > 1 & < 3 years of enrolment
  • LVEF ≤ 25 months of screening visit if index MI was ≥ 3 years of enrolment
  • Proven, necessary or appropriate medications (e.g. beta-blocker, ACE inhibitor / ARB, statin, and anti-platelet)
  • In normal sinus rhythm (ECG documented) ≤ 8 weeks prior to the screening Holter
  • Written informed consent
  • Able and willing to complete the screening Holter, including the six-minute hall walk

Additional inclusion criterion (eligibility for randomization).

  • Abnormal HRT & TWA (core lab interpretation) on Holter performed at least 2 months after the index MI and the specified time after coronary revascularization
  • In normal sinus rhythm (ECG documented) within 8 weeks prior to the screening Holter
  • In normal sinus rhythm for ≥ 18 hours of the 24 hr screening Holter as determined by the study Holter Core Lab

Exclusion criteria

(randomization or registry).

  • Use of antiarrhythmic drugs
  • Clinical indication for permanent pacemaker or a cardiac resynchronization device
  • Clinical indication for an ICD or cardiac resynchronization ICD
  • Prior implantation of a pacemaker, ICD, or Cardiac Resynchronization device
  • Any condition, in the investigator's judgment, that would limit life expectancy to < 12 months
  • Chronic renal failure (hemodialysis or peritoneal dialysis)
  • Active ischemia that is amenable to revascularization if not previously revascularized
  • Participation in another trial that may interfere with the REFINE ICD results.
  • Pregnancy
  • Inability to comply with the follow-up schedule

Treatment and study plan

Implantable Cardioverter Defibrillator + Usual Care

Device

Any Medtronic approved single chamber or dual chamber implantable cardioverter defibrillator (ICD)

Other names: Implantable Cardioverter Defibrillator, ICD

Usual Care

Other

Usual post-MI care

Other names: Standard medical therapy alone

Primary outcomes

  1. Mortality

    Time frame: Minimum of 18 months of follow-up (average follow-up of 5 years).

Secondary outcomes

  1. Cardiac death

    Time frame: Average follow-up 5 years.

  2. Arrhythmic death

    Time frame: Average follow-up 5 years.

  3. Arrhythmic syncope

    Time frame: Average follow-up 5 years.

  4. Appropriate ICD therapies

    Time frame: Average follow-up 5 years.

  5. Quality of life

    Time frame: Average follow-up 5 years.

  6. Inappropriate ICD therapies

    Time frame: Five years (average)

Sponsors and collaborators

Lead sponsor

University of Calgary

Other

Collaborators

  • Accelerating Clinical Trials Consortium
  • Alberta Innovation and Science
  • Canadian Institutes of Health Research (CIHR)
  • Cardiac Arrhythmia Network of Canada
  • GE Healthcare
  • Medtronic

Registry information

Official study title

Risk Estimation Following Infarction Noninvasive Evaluation - ICD Efficacy

Acronym: REFINE-ICD

Important dates

Study start
2011
Primary completion
2024
Study completion
2024
First posted
May 7, 2008
Registry last updated
May 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.